Condition deep-dive · 6 min read

Lower back pain supplement stack — what helps beyond movement therapy

Updated 2026-05-16 · Reviewed by SupplementScore editors · No sponsorships

Chronic low back pain is the leading cause of years lived with disability worldwide. The evidence-based pillars are exercise therapy (most consistent benefit across trials), CBT and pain neuroscience education, manual therapy in selected patients, and judicious medication. The supplement layer that has any clinical-trial support is small: bioavailable curcumin for inflammatory contribution, vitamin D correction in confirmed deficiency, magnesium for muscle-tension components, and PEA (palmitoylethanolamide) for nerve-pain features. None of these substitute for the movement and behavioural foundation; they are adjuncts at best.

Read this first. Red flags warranting prompt evaluation include: severe night pain unrelieved by position, fever, unintended weight loss, history of cancer, bowel/bladder dysfunction (cauda equina syndrome), saddle anesthesia, progressive neurological deficit, recent trauma, IV drug use, immunosuppression, or first-onset back pain age >50. New radiating leg pain with weakness or numbness warrants assessment. The supplement layer is for non-specific chronic low back pain — not for these clinical presentations.

What has trial evidence

Tier 2 evidence · Inflammatory contribution

Curcumin (bioavailable formulation)

500 mg b.i.d. of a bioavailable curcumin (phytosome/Meriva, liposomal, BCM-95, or piperine-formulated) with fat-containing meals

Curcumin has strong knee-OA evidence; lower back pain trials are smaller but supportive when the pain has an inflammatory component (degenerative disc disease, facet arthropathy, sacroiliitis). Effect sizes are modest, comparable to short-term NSAID effects but with much better GI safety profile — relevant for users who can't take chronic NSAIDs. Stop 2 weeks before scheduled surgery (mild anticoagulant effect).

Tier 2 evidence · In confirmed deficiency only

Vitamin D3

2,000–4,000 IU/day to a 25-OH-D target of 30–50 ng/mL

Observational studies consistently link low vitamin D status to chronic pain severity and prevalence including chronic low back pain. Interventional trials are mixed but show modest pain reductions when deficiency is corrected. Test 25-OH-D first; supplement only if low. The intervention is correcting deficiency — not "vitamin D for back pain" as a general protocol.

Tier 2 evidence · Muscle-tension component

Magnesium glycinate

300–400 mg elemental magnesium daily, often evening dose

Magnesium is involved in skeletal muscle function and has small pain-relevant trial signals in conditions with muscle-tension components. Useful where chronic low back pain has paraspinal muscle tightness, cramping, or sleep disruption from pain. Avoid in eGFR <30; loose stools at higher doses.

Tier 2 evidence · Sciatica / neuropathic features

Palmitoylethanolamide (PEA)

600 mg b.i.d. (1200 mg/day) of ultramicronised PEA

Indena and Epitech-formulated micronised/ultramicronised PEA has trial evidence in sciatica (Guida 2010) and chronic low back pain with neuropathic features. The mechanism — endogenous fatty acid amide acting on PPAR-α and modulating glial activation — fits the neuro-inflammatory component of nerve-pain back pain. Notably absent from US OTC channels; better availability in Europe.

Tier 3 evidence · Boswellia adjunct

Boswellia serrata (AKBA-standardised)

300–500 mg b.i.d. standardised to ≥30% AKBA

Most evidence is in knee OA, but the 5-LOX inhibition mechanism is plausibly relevant for inflammatory back pain components. Reasonable as a curcumin substitute or stacked adjunct in users who don't tolerate curcumin or for whom curcumin alone is insufficient.

The movement and behavioural foundation — typically much higher yield than supplements

The evidence base for chronic low back pain consistently favours active over passive interventions. Higher-yield than any supplement:

Graded exercise therapy — any form (walking, swimming, resistance, Pilates, yoga); the best exercise is the one you'll do consistently.
Specific therapy approaches — McKenzie method (extension-biased) for centralising disc-related pain; motor control / stability training; physical therapy guidance.
Pain neuroscience education (PNE) — understanding chronic pain biology meaningfully reduces fear-avoidance and pain catastrophising.
CBT for chronic pain — moderate effect size on disability and pain interference.
Sleep optimisation — poor sleep amplifies pain sensitivity; chronic pain disrupts sleep — break the cycle.
Weight management — meaningful effect on axial-loading pain over 6–12 months of sustained loss.
Smoking cessation — smoking is independently associated with worse low back pain and slower recovery.
Ergonomic optimisation — workstation, lifting mechanics, mattress (firmness preference is individual).

What to skip

Chronic opioids — minimal long-term benefit for chronic non-cancer pain; meaningful harms (tolerance, dependence, opioid-induced hyperalgesia, overdose).
Long-term high-dose NSAIDs — useful short-term but cardiovascular, renal, and GI burden limits chronic use; supplement layer should partially substitute for chronic NSAIDs.
"Back support" supplements with proprietary blends — sub-therapeutic doses of curcumin, MSM, and glucosamine bundled with herbal fillers.
Glucosamine/chondroitin for low back pain specifically — joint cartilage evidence doesn't transfer to spinal disc pathology.
Magnetic devices, copper bracelets, kinesiotape claims of structural change — placebo-grade evidence; harmless but not effective on pain pathophysiology.
Spinal manipulation alone for chronic non-radicular pain — modest benefit at best in chronic cases; better as adjunct to active therapy than standalone.

What to track

Oswestry Disability Index (ODI), Roland-Morris Disability Questionnaire, or NRS pain scale paired with simple function questions (walking tolerance, sitting tolerance, stair climbing). Reassess at 8–12 weeks of any supplement intervention. If pain or function hasn't measurably improved at 12 weeks of consistent dosing, the supplement isn't the rate-limiting step.

Practical quick-start. Establish the movement foundation first — graded exercise therapy you can sustain, physical therapy if needed, sleep, weight management, and pain neuroscience education. Test 25-OH-D and correct if low. Layer in a 12-week trial of bioavailable curcumin 500 mg b.i.d. for inflammatory pain pattern; add magnesium glycinate evenings if muscle tension or sleep disruption are prominent. If radicular / nerve-pain features dominate, PEA 600 mg b.i.d. is the better add-on. Reassess function and pain at 12 weeks.

Educational reference, not medical advice. Red-flag features warrant prompt clinical evaluation. Discuss any supplement change with a qualified clinician, especially if on prescription pain medication or anticoagulants.